User:Lan.wang17/Enter your new article name here

Matthew Chervenak is the founder, President and CEO of General Biologic (GBI), a China-focused healthcare consulting and data intelligence company.[1] He also serves as the Chairman of the Shanghai American Chamber of Commerce- Healthcare Committee.[2] Prior to establishing General Biologic, Chervenak was a strategist at Sapient Corporation in New York City and researcher at New York University Medical Center and the National Institutes of Health.[3] Chervenak graduated with a B.S. in Biology from Pennsylvania State University. [4]


Chervenak regularly contributes to international publications and speaks at industry conferences about China's pharmaceutical and biotechnology sectors. Chervenak believes that China is an ideal base for global biogenerics.[5] In his China Business Review editorial, Chervenak said that China's low-cost, highly skilled technologists and scientists, a strong track record in life-science research, a high-quality returnee pool, advantageous policies and tax treatment, and China's entrepreneurial culture makes it a bright future for China's life sciences industry.[6] Even in the controversial topic of IP in the life sciences field in China, according to Chervenak, as long as a foreign biotech firm protects its IP for the most lucrative markets, it is usually not worth being overly concerned about a Chinese company violating IP use in China, where the market is still small.[7]


References

edit
edit